Press release
Ponchiqs Developers Announce Launch of an FPS Game + Mobile App
Ponchiqs blends a first-person shooter game with exciting modes and a mobile app. Get ready for a new game ecosystem.Image: https://www.abnewswire.com/uploads/3837b29eec899b4ce397c374e1057f61.png
ISTANBUL - April 26, 2024 - The developers behind Ponchiqs [https://www.ponchiqs.com/] are launching their metaverse game that combines a first-person shooter game with exciting modes, and a Mobile App in June. With this unique combination, this development team is poised to deliver an unforgettable gaming experience. Players can immerse themselves in a world like no other to join forces with a charismatic unicorn, embark on a daring mission, and save the world.
Web3 games were exciting at first but have failed to retain non-crypto natives. Many Web3 games require players to go through complex set-up processes that can turn off players who are looking for entertainment. Additionally, some Web3 games are simply DeFi apps disguised as games and lack immersive gameplay. For these reasons, most Web3 games have failed to retain active users. Many first-person shooter games also do not offer enough excitement to keep players engaged in the long term.
"We've developed Ponchiqs to offer thrilling gameplay supported by strong tokenomics and a robust economy," says Ponchiqs CEO Gokhan Gezici. "Beyond that, we aim to be the best at uniting airdrop logic with in-game missions."
Ponchiqs offers a gripping adventure where players can earn rewards, access customizable psycho powers, and interact with fellow Ponchiqs through an engaging multiplayer mode. As such, Ponchiqs will offer gamers more fun, better quality, and higher profits. Get ready for a new game ecosystem.
The team behind Ponchiqs has leveraged their extensive experience in the gaming industry, software technologies, and best practices in entertainment to build this game. In fact, the CMO and COO Berk Dogan was a COO & Partner at Seedify.fund - one of the biggest Web3 gaming incubators. Cem Ucar, the CTO, is an experienced VFX artist and game designer with experience at Netflix, Marvel Entertainment, and 20th Century Studios.
Ponchiqs offers gamers an immersive and thrilling FPS experience, coupled with captivating modes and rewarding economics. As such, Ponchiqs addresses ongoing Web3 gaming challenges [https://techcrunch.com/2023/09/19/web3-gaming-investor-survey/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHl5hSgzWkJMEXzOdh21BVnOjoUzcy4JHTO3xMA5-8ELqScpLvDHvzNp9Wq-wYZh5EUlJKq-p8cxkTiJgyGarGs3lL9BQO7C5tp62vP0c4CpobrYqG46XXXLYkM6ymDtktfw1mNoETdWQ-LUeV0tVHipwot9MCCYrwu_A4_5uFo8] while offering a fulfilling and exciting gaming experience that will keep players coming back for more.
About Ponchiqs
Ponchiqs is a meta-universe that combines a first-person shooter game, exciting modes, and a mobile app. Backed by a strong team with experience in the gaming and entertainment industries, this game is poised to offer players thrilling gameplay and rewarding tokenomics.
For Media inquires please contact Berk Dogan at info@ponchiqs.com [mailto:info@ponchiqs.com].
Media Contact
Company Name: Ponchiqs
Contact Person: Berk Dogan
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ponchiqs-developers-announce-launch-of-an-fps-game-mobile-app]
City: Istanbul
Country: Turkey
Website: https://www.ponchiqs.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ponchiqs Developers Announce Launch of an FPS Game + Mobile App here
News-ID: 3478077 • Views: …
More Releases from ABNewswire
Clostridioides Difficile Infection Market Size in the 7MM was ~USD 500 million i …
DelveInsight's "Clostridioides Difficile Infection Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Clostridioides Difficile Infection, historical and forecasted epidemiology as well as the Clostridioides Difficile Infection therapeutics market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Clostridioides Difficile Infection Market with DelveInsight's In-Depth Report @ Clostridioides Difficile Infection Treatment Market Size…
Triple Negative Breast Cancer Market Set for Robust Growth Through 2034Innovativ …
Driven by rise of immunotherapies, antibody-drug conjugates, and precision-targeted approaches, TNBC market is projected to expand from USD 4.7 billion in 2025 to USD 7.1 billion by 2034, marking a CAGR of 4.7% across the 7MM. Leading players like AstraZeneca, Pfizer, Gilead Sciences, BioNTech, Astellas Pharma are at forefront, advancing next-generation therapies such as ADC platforms, checkpoint inhibitors, and novel vaccines that aim to improve survival outcomes and redefine patient…
Limb Girdle Muscular Dystrophy Therapeutics Market Size in the 7MM is expected t …
DelveInsight's " Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Limb Girdle Muscular Dystrophy, historical and forecasted epidemiology, as well as the Limb Girdle Muscular Dystrophy Market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Limb Girdle Muscular Dystrophy Market with DelveInsight's In-Depth Report @ Limb Girdle Muscular…
Non-Cystic Fibrosis Bronchiectasis Competitive Landscape 2025: Clinical Trial An …
Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others.
According to DelveInsight's analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline features over 16 leading companies actively advancing more than 17 therapeutic candidates, with ongoing evaluations of their clinical trials, mechanisms of action, routes of administration, and developmental…
